A. No. The FDA thinks that scientifically legitimate analysis performed under an IND application may be the best way to ascertain what patients could take advantage of the use of drugs derived from cannabis. The FDA supports the conduct of that study by: Cannabidiol continues to be Employed in https://mannersc680ace4.techionblog.com/profile